In experimental settings, those agents reduced collagen production and fibrosis and decreased vascular endothelial growth factor (VEGF) release, a proangiogenic factor associated with pulmonary arterial hypertension [54]. This evidence concerns the gene VEGFA and pulmonary arterial hypertension.